Biopharma Dealmaking Quarterly Statistics, Q4 2012

A look at financing, M&A, and alliance activity October – December 2012

At $4.2 billion, biopharma financing in Q4 2012 showed a 36% increase over Q3 with FOPOs again dominating as the most popular deal type. With 34 finalized biopharma M&As, Q4 was the most active quarter of all 2012 for acquisitions. The 108 biopharma alliances completed had a combined potential deal value of almost $2 billion; Johnson & Johnson, with seven tie-ups, was the busiest pharmaco during Q4.

Biopharma financing in the final quarter of 2012 reached $4.2 billion, a 36% increase over Q3’s $3.1 billion, again boosted by a strong showing from follow-on public offerings. The fourth quarter’s total, albeit the highest single quarter total of the year, still wasn’t enough to propel 2012’s financing aggregate of $13.6 billion above the $14.1 billion raised in 2011. (See Exhibit 1.) However, keep in mind that 2011’s figure did include Shanghai Pharmaceuticals Holding Co. Ltd.’s $2 billion IPO on the Hong Kong Exchange, [See Deal] a definite outlier, and one, that when taken out of the equation, puts 2012 ahead.

Exhibit 1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.